MIGLIETTA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.464
AS - Asia 1.982
EU - Europa 1.674
AF - Africa 584
SA - Sud America 533
OC - Oceania 60
Continente sconosciuto - Info sul continente non disponibili 31
Totale 8.328
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.122
SG - Singapore 724
BR - Brasile 360
IT - Italia 319
DE - Germania 306
CN - Cina 287
HK - Hong Kong 271
FI - Finlandia 201
VN - Vietnam 76
PL - Polonia 69
IN - India 60
GB - Regno Unito 58
NL - Olanda 56
SE - Svezia 56
FR - Francia 50
AT - Austria 49
RU - Federazione Russa 47
AR - Argentina 42
BJ - Benin 33
KR - Corea 32
ID - Indonesia 30
TR - Turchia 30
CI - Costa d'Avorio 28
IE - Irlanda 28
CZ - Repubblica Ceca 27
IQ - Iraq 27
PS - Palestinian Territory 27
ES - Italia 26
MX - Messico 25
TN - Tunisia 25
CA - Canada 24
JO - Giordania 24
CH - Svizzera 23
JP - Giappone 23
BS - Bahamas 22
GT - Guatemala 22
MK - Macedonia 22
SA - Arabia Saudita 22
ZA - Sudafrica 22
AE - Emirati Arabi Uniti 21
CO - Colombia 21
EG - Egitto 21
JM - Giamaica 21
ET - Etiopia 20
HR - Croazia 20
NO - Norvegia 19
TT - Trinidad e Tobago 19
UY - Uruguay 19
AO - Angola 18
KZ - Kazakistan 18
SI - Slovenia 18
ZW - Zimbabwe 18
BY - Bielorussia 17
CD - Congo 17
CR - Costa Rica 17
CY - Cipro 17
HN - Honduras 17
IL - Israele 17
IS - Islanda 17
LB - Libano 17
MN - Mongolia 17
MW - Malawi 17
NP - Nepal 17
PA - Panama 17
PH - Filippine 17
RS - Serbia 17
UA - Ucraina 17
BA - Bosnia-Erzegovina 16
BB - Barbados 16
CU - Cuba 16
CW - ???statistics.table.value.countryCode.CW??? 16
DK - Danimarca 16
EC - Ecuador 16
GN - Guinea 16
IR - Iran 16
KE - Kenya 16
MY - Malesia 16
NI - Nicaragua 16
SK - Slovacchia (Repubblica Slovacca) 16
BO - Bolivia 15
CL - Cile 15
DO - Repubblica Dominicana 15
GM - Gambi 15
LU - Lussemburgo 15
MA - Marocco 15
MD - Moldavia 15
ME - Montenegro 15
MG - Madagascar 15
ML - Mali 15
UZ - Uzbekistan 15
VC - Saint Vincent e Grenadine 15
XK - ???statistics.table.value.countryCode.XK??? 15
ZM - Zambia 15
AL - Albania 14
AU - Australia 14
BG - Bulgaria 14
CV - Capo Verde 14
AD - Andorra 13
AM - Armenia 13
AZ - Azerbaigian 13
Totale 7.700
Salva come PNG Salva come JPEG
Città #
Singapore 487
Ashburn 404
Fairfield 379
Chandler 281
Hong Kong 237
Munich 229
Woodbridge 183
Houston 164
Cambridge 146
Seattle 143
Helsinki 141
Ann Arbor 126
Wilmington 116
Beijing 100
Boardman 78
Padova 61
Los Angeles 58
Chicago 45
Santa Clara 43
Bytom 40
San Diego 37
Medford 35
Princeton 35
São Paulo 32
Cotonou 31
New York 31
Ho Chi Minh City 30
Turku 29
Abidjan 27
Des Moines 27
Hefei 27
Roxbury 27
Buffalo 24
London 24
Vienna 24
Amman 22
Dublin 21
Nassau 21
Salt Lake City 20
Warsaw 20
Milan 19
Nuremberg 19
Rome 19
Harare 17
Redondo Beach 17
Ulan Bator 17
Bridgetown 16
Conakry 16
Dallas 16
Managua 16
Addis Ababa 15
Kingston 15
Lusaka 15
Panama City 15
Podgorica 15
San José 15
Tashkent 15
Willemstad 15
Antananarivo 14
Bamako 14
Kingstown 14
Lilongwe 14
Luanda 14
Reykjavik 14
Villafranca Padovana 14
Andorra la Vella 13
Dakar 13
Guatemala City 13
Havana 13
Kampala 13
Kinshasa 13
Montevideo 13
Nairobi 13
Pristina 13
Pune 13
Seoul 13
Amsterdam 12
Baghdad 12
Brooklyn 12
Hanoi 12
Jinan 12
Jyväskylä 12
Libreville 12
Minsk 12
Skopje 12
Tampa 12
Baku 11
Castries 11
Dong Ket 11
Jeddah 11
Lappeenranta 11
Maputo 11
Nanjing 11
Ramallah 11
Tokyo 11
Tunis 11
Vientiane 11
Zhengzhou 11
Dar es Salaam 10
Dili 10
Totale 4.810
Salva come PNG Salva come JPEG
Nome #
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 316
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 232
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 226
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 218
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 206
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 206
Immune characterization of breast cancer metastases: Prognostic implications 197
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 192
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 177
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 177
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 177
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 174
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 168
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 164
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 163
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 162
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 157
Evolution of HER2-low expression from primary to recurrent breast cancer 157
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 148
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value 148
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 143
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 138
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 135
Breast cancer biological characterization - Evaluation of the prognostic and/or predictive role of clinical, pathological and molecular biomarkers to dissect breast cancer heterogeneity: focus on estrogen-low breast cancer 134
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 134
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 131
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 130
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 130
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 130
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 129
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives 127
Abdominal Wall Reconstruction: Biomaterialsand Tissue Engineering Biomaterials 126
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 126
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 124
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 114
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 112
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 103
Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability? 103
Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival 101
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer 101
Postsurgical Pyoderma Gangrenosum in a Breast Cancer Patient: A Case Report and Literature Review 101
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 99
Cardiac Safety of Adjuvant Trastuzumab and Paclitaxel for HER2+ early breast cancer patients published in Abstract Book of the 21th National Congress of Italian Association of Medical Oncology (AIOM) 25-27 October, 2019 - Rome, Italy Abstracts 99
PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study 98
Therapeutic strategies for the management of hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) breast cancer: A review of the current literature 96
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer 95
Olaparib for advanced breast cancer 92
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer 92
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 91
Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases 89
Complicanze tromboemboliche in chirurgia plastica: osservazioni su 20000 procedure di chirurgia maggiore 87
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial 87
ALLSTAR: inference of reliAble causaL ruLes between Somatic muTAtions and canceR phenotypes 86
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 85
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 82
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy 79
An overview of immune checkpoint inhibitors in breast cancer 78
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications 77
Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients 75
Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials 74
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 70
How can we refine the prognostic stratification of triple-negative breast cancer? 65
HER2: a never ending story 64
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 64
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 58
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 52
Managing sexual health challenges in breast cancer survivors: A comprehensive review 49
Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications 26
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial 24
Totale 8.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.199
article - articoli 26.417
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 295
Totale 53.911
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021491 0 0 0 0 16 113 45 49 72 107 48 41
2021/2022562 23 48 55 27 64 33 68 34 39 17 39 115
2022/2023556 93 70 35 68 54 59 20 28 88 3 30 8
2023/2024434 44 48 50 27 32 59 35 16 7 27 34 55
2024/20252.233 1 150 71 77 162 115 183 255 205 164 339 511
2025/20263.391 452 488 1.107 1.289 55 0 0 0 0 0 0 0
Totale 8.470